Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer
| Autor: | D. McRae, Zachary D. Horne, Robert L. Hong, Sana D. Karam, David Duhamel, Nadim M. Nasr |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Lung Neoplasms Stage IIIA Stage IIIB medicine.medical_treatment Nodal Kaplan-Meier Estimate Radiosurgery Disease-Free Survival Age Fiducial Markers Carcinoma Non-Small-Cell Lung medicine Humans Radiology Nuclear Medicine and imaging External beam radiotherapy Progression-free survival Lung cancer Radiation treatment planning Radiometry Boost SABR Aged Proportional Hazards Models Cyberknife Aged 80 and over Univariate analysis SBRT Dose escalation business.industry Research Radiotherapy Planning Computer-Assisted Chemoradiotherapy Middle Aged medicine.disease Radiation therapy Oncology Radiology Nuclear Medicine and imaging Locally advanced Female Radiology business Nuclear medicine |
| Zdroj: | Radiation Oncology (London, England) |
| ISSN: | 1748-717X |
| Popis: | Introduction Low survival outcomes have been reported for the treatment of locally advanced non small cell lung cancer (LA-NSCLC) with the standard of care treatment of concurrent chemoradiation (cCRT). We present our experience of dose escalation using stereotactic body radiosurgery (SBRT) following conventional cCRT for patients with LA-NSCLC. Methods Sixteen patients with a median age of 67.5 treated with fractionated SBRT from 2010 to 2012 were retrospectively analyzed. Nine (56%) of the patients had stage IIIB, 6 (38%) has stage IIIA, and 1 (6%) had recurrent disease. Majority of the patients (63%) presented with N2 disease. All patients had a PET CT for treatment planning. Patients received conventional cCRT to a median dose of 50.40 Gy (range 45–60) followed by an SBRT boost with an average dose of 25 Gy (range 20–30) given over 5 fractions. Results With a median follow-up of 14 months (range, 1–14 months), 1-year overall survival (OS), progression free survival (PFS), local control (LC), regional control (RC), and distant control (DC) rates were, 78%, 42%, 76%, 79%, and 71%, respectively. Median times to disease progression and regional failure were 10 months and 18 months, respectively. On univariate analysis, advanced age and nodal status were worse prognostic factors of PFS (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink